Figure 4.

INK-128 and JNJ-26481585 suppress gallbladder cancer growth and metastasis in mouse models

(A) Luciferase-tagged GBC-SD cells were transplanted subcutaneously in mice, and tumor growth and metastasis were measured by the luminescence Xenogen system. Representative images of primary tumor and lung metastasis from 1 of 6 mice per group were shown in the upper panel and lower panel. The number of mice that developed lung metastasis is also indicated. (B) Primary tumor growth in mice treated with gemcitabine, JNJ-26481585, gemcitabine and JNJ-26481585, or DMSO control was measured by the luminescence Xenogen system. (C) Primary tumor growth in mice treated with gemcitabine, INK-128, gemcitabine and INK-128, or DMSO control was measured by the luminescence Xenogen system. (D) Body weight were monitored at week 6 for all six groups of mice. (E) HDAC1 and HDAC2 mRNA expression in xenograft tumor tissues treated with DMSO control, JNJ-26481585, gemcitabine, or gemcitabine and JNJ-26481585. (F) Protein level of AKT (Ser-473), AKT (Thr-308), and p70S6K1 (Thr-389) in xenograft tumor tissues administrated with DMSO control, INK-128, gemcitabine, or gemcitabine and INK-128.